News

At 8 months follow-up, 86.0% of patients with rheumatoid arthritis were in remission and 94.2% exhibited low disease activity.

The announcement follows the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses

This analysis among Japanese patients highlights the potential of apremilast for psoriasis patients not responding to topical therapy who may have limited systemic treatment options.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.

The CATALYST trial sheds light on the true prevalence of hypercortisolism among difficult-to-control type 2 diabetes, with data at ADA 2024 shedding light on adrenal abnormalities and presence among subgroups.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

Dubinett and Spira rejoin Lungcast for an update on their team's research into lung cancer interception.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

Study results highlight the impact of continuous glucose monitoring on glucose control and HbA1c improvements in patients with type 2 diabetes, regardless of treatment regimen.

Teva Pharmaceuticals’ launch of an authorized generic of liraglutide injection 1.8 mg (Victoza) for type 2 diabetes makes it the first-ever generic GLP-1.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

Vutrisiran achieved statistically significant reductions in primary and all secondary endpoints for patients with ATTR-CM in the HELIOS-B trial.

These data highlight the efficacy of ritlecitinib for patients with alopecia areata and extensive hair loss at baseline.

Anastasia Albanese-O'Neill, PhD, APRN, joins Diabetes Dialogue to discuss newly released consensus guidance on monitoring of early-stage type 1 diabetes spearheaded by Breakthrough T1D.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

FDA approves pitolisant for excessive daytime sleepiness and cataplexy in pediatric patients aged ≥ 6 years with narcolepsy.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

In this episode, hosts are joined by Grazia Aleppo, MD, for a discussion on the use of inhaled insulin following the INHALE-3 trial and relevant updates in diabetes technology at ADA 2024.

An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.

Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.

Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.

Omnipod 5 improved HbA1c from 8.2% to 7.4% in 13 weeks among adults with type 2 diabetes in the SECURE-T2D trial, with a nearly 5-hour increase in time in range per day.

ADA study highlights disparities in CGM access for children with type 1 diabetes, showing delays for publicly insured and minority children.

New data from INHALE-3 at ADA 84th Scientific Sessions show inhaled insulin (Afrezza) is safe, effective for type 1 diabetes, improving glycemic control and HbA1c goals.

Participants assigned to a 4-day energy balance diet plus oral bisphenol A administration at 50 μg/kg body weight experienced significant decreases in peripheral insulin sensitivity.